Paper38575868
CGRP-targeted medication in chronic migraine - systematic review.
Oliveira R and 2 others. J Headache Pain, 2024. Cited by 60 papers, by iCite.
Cite this record
ConductScience Library. CGRP-targeted medication in chronic migraine - systematic review. Papers, record 38575868. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38575868
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Calcitonin Gene-Related Peptide | Major topic |
| Migraine Disorders | Major topic |
| Humans | |
| Antibodies, Monoclonal | |
| Receptors, Calcitonin Gene-Related Peptide | |
| Calcitonin Gene-Related Peptide Receptor Antagonists |
Source PubMed
References56
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35690723 | European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. | J Headache Pain | 2022 | https://conductscience.org/library/papers/35690723 | PubMed |
| 2 | 27389092 | Chronic migraine: risk factors, mechanisms and treatment. | Nat Rev Neurol | 2016 | https://conductscience.org/library/papers/27389092 | PubMed |
| 3 | 35146696 | Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score. | CNS Drugs | 2022 | https://conductscience.org/library/papers/35146696 | PubMed |
| 4 | 30446596 | Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. | Neurology | 2018 | https://conductscience.org/library/papers/30446596 | PubMed |
| 5 | 22300068 | Adherence with migraine prophylaxis in clinical practice. | Pain Pract | 2012 | https://conductscience.org/library/papers/22300068 | PubMed |
| 6 | 32517693 | Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. | J Headache Pain | 2020 | https://conductscience.org/library/papers/32517693 | PubMed |
| 7 | 35383922 | Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid. | Headache | 2022 | https://conductscience.org/library/papers/35383922 | PubMed |
| 8 | 34409517 | Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series. | Neurol Sci | 2021 | https://conductscience.org/library/papers/34409517 | PubMed |
| 9 | 31563224 | Migraine: Epidemiology, Burden, and Comorbidity. | Neurol Clin | 2019 | https://conductscience.org/library/papers/31563224 | PubMed |
| 10 | 37072224 | Late Response to Anti-CGRP Monoclonal Antibodies in Migraine: A Multicenter Prospective Observational Study. | Neurology | 2023 | https://conductscience.org/library/papers/37072224 | PubMed |
| 11 | 33615840 | CGRP monoclonal antibody prevents the loss of diffuse noxious inhibitory controls (DNIC) in a mouse model of post-traumatic headache. | Cephalalgia | 2021 | https://conductscience.org/library/papers/33615840 | PubMed |
| 12 | 34644203 | Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study. | Cephalalgia | 2022 | https://conductscience.org/library/papers/34644203 | PubMed |
| 13 | 32546227 | European headache federation consensus on the definition of resistant and refractory migraine : Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). | J Headache Pain | 2020 | https://conductscience.org/library/papers/32546227 | PubMed |
| 14 | 36548744 | OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine. | Toxins (Basel) | 2022 | https://conductscience.org/library/papers/36548744 | PubMed |
| 15 | 32602955 | Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review. | Headache | 2020 | https://conductscience.org/library/papers/32602955 | PubMed |
| 16 | 27206958 | Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents. | Cephalalgia | 2017 | https://conductscience.org/library/papers/27206958 | PubMed |
| 17 | 32122324 | Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. | J Headache Pain | 2020 | https://conductscience.org/library/papers/32122324 | PubMed |
| 18 | 32810212 | Differential medication overuse risk of novel anti-migraine therapeutics. | Brain | 2020 | https://conductscience.org/library/papers/32810212 | PubMed |
| 19 | 34873540 | Quality of Life and Disability Among Migraine Patients: A Single-Center Study in AlAhsa, Saudi Arabia. | Cureus | 2021 | https://conductscience.org/library/papers/34873540 | PubMed |
| 20 | 33880725 | Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review. | Pain Ther | 2021 | https://conductscience.org/library/papers/33880725 | PubMed |
Cited by53
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 60 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42980719 | Real-World Effectiveness and Utilisation of Anti-CGRP Monoclonal Antibodies for Migraine Prevention in a Public Healthcare System. | Drugs Real World Outcomes | 2026 | https://conductscience.org/library/papers/42980719 | PubMed |
| 42941670 | Middle Meningeal Artery Embolization Using Non-Adhesive Liquid Embolic Agents for Chronic Resistant Migraine: Interim Feasibility and Safety Analysis of a Prospective Single-Arm Trial. | J Clin Med | 2026 | https://conductscience.org/library/papers/42941670 | PubMed |
| 42939289 | Triptans and Lasmiditan Are Safe and Effective in Patients with Migraine Attacks Associated with Neurodevelopmental Disorders: A Single-Center Prospective Clinical Case Series. | Brain Sci | 2026 | https://conductscience.org/library/papers/42939289 | PubMed |
| 42922561 | Low-Dose Interleukin-2 Resolves Stress-Induced Chronic Sensitization Independent of Opioid Receptor Signaling. | bioRxiv | 2026 | https://conductscience.org/library/papers/42922561 | PubMed |
| 42902147 | Targeting neuronal FKBP5 attenuates mechanical allodynia by suppressing NF-κB-mediated neuroinflammation in an NTG-induced chronic migraine mouse model. | J Headache Pain | 2026 | https://conductscience.org/library/papers/42902147 | PubMed |
| 42853529 | Migraine and Obesity: From Shared Mechanisms to Therapeutic Strategies. | Neurol Ther | 2026 | https://conductscience.org/library/papers/42853529 | PubMed |
| 42814345 | Persistence and Reasons for Treatment Discontinuation of Anti-CGRP Therapies in Migraine Prophylaxis: A Systematic Review and Meta-analysis of Real-World Studies. | Pain Ther | 2026 | https://conductscience.org/library/papers/42814345 | PubMed |
| 42741009 | A multidisciplinary multicentric approach to the identification of predictive biomarkers of response to erenumab - the protocol of the phase 4, European, open-label controlled trial of the BIOMIGA project. | Front Neurol | 2026 | https://conductscience.org/library/papers/42741009 | PubMed |
| 42662157 | OnabotulinumtoxinA for chronic migraine: A real-life multicenter study of 479 patients. | Ther Adv Neurol Disord | 2026 | https://conductscience.org/library/papers/42662157 | PubMed |
| 42548107 | Global, regional, and national burden of migraine in postmenopausal women: a 32-year analysis from the global burden of disease study 1990-2021. | J Oral Facial Pain Headache | 2026 | https://conductscience.org/library/papers/42548107 | PubMed |
| 42469638 | From tooth pain to trigeminal sensitization: translational models, experimental readouts, and mechanism-guided therapeutic opportunities in odontogenic and headache-related orofacial pain. | J Headache Pain | 2026 | https://conductscience.org/library/papers/42469638 | PubMed |
| 42399797 | Predictive factors of response to anti-CGRP pathway drugs in people with multiple sclerosis. | J Headache Pain | 2026 | https://conductscience.org/library/papers/42399797 | PubMed |
| 42349425 | A highly efficient method to differentiate CGRP-expressing peptidergic nociceptors from human induced pluripotent stem cells. | Stem Cell Reports | 2026 | https://conductscience.org/library/papers/42349425 | PubMed |
| 42238828 | Efficacy of Erenumab in Patients With Treatment-Resistant Chronic Migraine and Medication Overuse Headache. | Neurosciences (Riyadh) | 2026 | https://conductscience.org/library/papers/42238828 | PubMed |
| 42220284 | An exploration of possible future non-pharmacological multidisciplinary treatments to potentiate withdrawal strategy and recovery from medication overuse headache (MOH): a narrative review. | J Oral Facial Pain Headache | 2026 | https://conductscience.org/library/papers/42220284 | PubMed |
| 42201619 | CGRP-targeted therapies for migraine and the risk of infection. | Intern Emerg Med | 2026 | https://conductscience.org/library/papers/42201619 | PubMed |
| 42168858 | Functional characterisation of dura mater αCGRP degradation fragments at vascular, immune, and CGRP receptor targets. | J Headache Pain | 2026 | https://conductscience.org/library/papers/42168858 | PubMed |
| 42147339 | Efficacy and safety of Chinese botanical drug decoctions for migraine: a Bayesian network meta-analysis. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42147339 | PubMed |
| 42032384 | Use of CGRP Monoclonal Antibodies in Japan, South Korea, and Taiwan: A Narrative Review. | Curr Pain Headache Rep | 2026 | https://conductscience.org/library/papers/42032384 | PubMed |
| 41987050 | Trends in migraine-specific medication consumption: a multinational analysis of 73 countries based on IQVIA-MIDAS database, 2015 to 2024. | J Headache Pain | 2026 | https://conductscience.org/library/papers/41987050 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CALCA | 796 | PubTator's text mining | https://conductscience.org/library/genes/796 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38575868
GET https://conductscience.org/api/papers/v1/38575868/references?page=2